Open AccessDrug safety for nursing-home residents
Author(s) -
Ulrike Junius-Walker,
Olaf Krause,
Petra A. Thürmann,
Simone Bernhard,
Ângela Fuchs,
Lisa Sparenberg,
Anja Wollny,
Regina Stolz,
Hannah Haumann,
Antje Freytag,
C.-M. Kirsch,
Svetlana Usacheva,
Stefan Wilm,
Birgitt Wiese
Publication year - 2021
Publication title -
deutsches ärzteblatt international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 60
ISSN - 1866-0452
DOI - 10.3238/arztebl.m2021.0297
Subject(s) - medicine , polypharmacy , nursing , medical prescription , intervention (counseling) , randomized controlled trial , family medicine , deprescribing , clinical trial , quality of life (healthcare) , patient safety , health care , intensive care medicine , surgery , pathology , economics , economic growth
The safety of drug use by nursing-home residents can be impaired by polypharmacy, potentially inappropriate medications (PIM), and neuroleptics, as well as by a lack of adequate interprofessional coordination in the nursing home. The goal of the HIOPP-3-iTBX Trial was to improve drug safety in nursing-home residents, including a reduction of PIM and/or neu - roleptic use, by means of a complex interprofessional intervention.